New drug tested in kids with rare Muscle-Weakening disease
NCT ID NCT06055959
Summary
This study aims to learn about the safety, drug levels in the body, and activity of an investigational drug called zilucoplan in children and teenagers (ages 2 to 18) with a rare autoimmune disease called generalized myasthenia gravis (gMG). The study will enroll about 8 participants to see how their bodies process the drug and if it helps control their disease symptoms over a 4-week period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Mg0014 20104
RECRUITINGSeoul, South Korea
-
Mg0014 20220
RECRUITINGSeoul, South Korea
-
Mg0014 40144
RECRUITINGMilan, Italy
-
Mg0014 40218
RECRUITINGWarsaw, Poland
-
Mg0014 40735
RECRUITINGGlasgow, United Kingdom
-
Mg0014 40736
RECRUITINGLondon, United Kingdom
-
Mg0014 40774
RECRUITINGKatowice, Poland
-
Mg0014 50168
WITHDRAWNChicago, Illinois, 60611, United States
-
Mg0014 50574
WITHDRAWNDenton, Texas, 76208, United States
Conditions
Explore the condition pages connected to this study.